Polyrizon Ltd. ( (PLRZ)) just unveiled an announcement. On April 7, 2026, Polyrizon Ltd. entered into definitive agreements with a single institutional investor for a registered direct offering of ...

Raanana, Israel, March 26, 2026 (GLOBE NEWSWIRE)-- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon” or the "Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, ...

Aegis Capital Corp. acted as exclusive placement agent for the offerings. Greenberg Traurig, P.A. acted as U.S. counsel to the Company and Meitar | Law Offices acted as Israeli counsel to the Company.

View Polyrizon Ltd. PLRZ stock quote prices, financial information, real-time forecasts, and company news from CNN.

Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE)-- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, ...

Raanana, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal ...

The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production ...

The MarketWatch News Department was not involved in the creation of this content. Raanana, Israel, Jan. 02, 2026 (GLOBE NEWSWIRE) -- As the 2025-2026 flu season intensifies across the United States, a ...

The Company signed a non-binding MOU with shareholders of Colugo. Colugo’s customer include the Israel Defense Forces, national first responders organizations and commercial companies Raanana, Israel, ...

Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (PLRZ) ...

The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted ...

Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has entered into definitive agreements ...